Research models to study lewy body dementia

被引：0
作者：
Suelen Lucio Boschen [1 ]
Aarushi A. Mukerjee [2 ]
Ayman H. Faroqi [1 ]
Ben E. Rabichow [3 ]
John Fryer [3 ]
机构：
[1] Department of Neuroscience, Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, 32224, FL
[2] Department of Neurosurgery, Mayo Clinic Jacksonville, 4500 San Pablo Rd, Jacksonville, 32224, FL
[3] Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, 200 First St. SW, Rochester, 55905, MN
[4] Translational Genomics Research Institute, 445 N 5th St, Phoenix, 850054, AZ
来源：
Molecular Neurodegeneration | / 20卷 / 1期
基金：
美国国家卫生研究院;
关键词：
Alpha-synuclein; Animal model; Beta-amyloid; Cell culture; Dementia with lewy body; Parkinson’s disease dementia; Synucleinopathy; Tau;
D O I：
10.1186/s13024-025-00837-w
中图分类号：
学科分类号：
摘要：
Lewy body dementia (LBD) encompasses neurodegenerative dementias characterized by cognitive fluctuations, visual hallucinations, and parkinsonism. Clinical differentiation of LBD from Alzheimer’s disease (AD) remains complex due to symptom overlap, yet approximately 25% of dementia cases are diagnosed as LBD postmortem, primarily identified by the presence of α-synuclein aggregates, tau tangles, and amyloid plaques. These pathological features position LBD as a comorbid condition of both Parkinson’s disease (PD) and AD, with over 50% of LBD cases exhibiting co-pathologies. LBD’s mixed pathology complicates the development of comprehensive models that reflect the full spectrum of LBD’s etiological, clinical, and pathological features. While existing animal and cellular models have facilitated significant discoveries in PD and AD research, they lack specificity in capturing LBD’s unique pathogenic mechanisms, limiting the exploration of therapeutic avenues for LBD specifically. This review assesses widely used PD and AD models in terms of their relevance to LBD, particularly focusing on their ability to replicate human disease pathology and assess treatment efficacy. Furthermore, we discuss potential modifications to these models to advance the understanding of LBD mechanisms and propose innovative research directions aimed at developing models with enhanced etiological, face, predictive, and construct validity. © The Author(s) 2025.
引用
收藏
相关论文
共 162 条
  • [31] Kaczynska K., Andrzejewski K., Chapter 40–6-hydroxydopamine-induced model of Parkinson’s disease, Genetics, neurology, behavior, and diet in Parkinson’, pp. 627-642, (2020)
  • [32] Nielsen M.S., Glud A.N., Moller A., Mogensen P., Bender D., Sorensen J.C., Et al., Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits, Acta Neurobiol Exp (Wars), 76, 3, pp. 199-211, (2016)
  • [33] Meredith G.E., Rademacher D.J., MPTP mouse models of Parkinson’s disease: an update, J Parkinsons Dis, 1, 1, pp. 19-33, (2011)
  • [34] Staal R.G., Sonsalla P.K., Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata, J Pharmacol Exp Ther, 293, 2, pp. 336-342, (2000)
  • [35] Ferro M.M., Bellissimo M.I., Anselmo-Franci J.A., Angellucci M.E.M., Canteras N.S., Da Cunha C., Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson’s disease: histological, neurochemical, motor and memory alterations, J Neurosci Methods, 148, 1, pp. 78-87, (2005)
  • [36] Imbert C., Bezard E., Guitraud S., Boraud T., Gross C.E., Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the macaque monkey, J Neurosci Methods, 96, 1, pp. 71-76, (2000)
  • [37] Bezard E., Brotchie J.M., Gross C.E., Pathophysiology of levodopa-induced dyskinesia: potential for new therapies, Nat Rev Neurosci, 2, 8, pp. 577-588, (2001)
  • [38] Decamp E., Schneider J., Attention and executive function deficits in chronic low-dose MPTP‐treated non‐human primates, Eur J Neurosci, 20, 5, pp. 1371-1378, (2004)
  • [39] Porras G., Li Q., Bezard E., Modeling Parkinson’s disease in primates: the MPTP model, Cold Spring Harb Perspect Med, 2, 3, (2012)
  • [40] Real C.C., Binda K.H., Thomsen M.B., Lillethorup T.P., Brooks D.J., Landau A.M., Selecting the best animal model of Parkinson’s disease for your research purpose: insight from in vivo PET imaging studies, Curr Neuropharmacol, 21, 5, pp. 1241-1272, (2023)
12345678910